Strong sales progress being made as distribution channel reorders continue
FREDERICK, Md., Oct. 21 /PRNewswire/ -- BioElectronics Corp. (BIEL), the maker of ActiPatch(R) Therapy, the drug free anti-inflammatory patch, with an embedded battery operated microchip delivering continuous pulse therapy that revolutionizes the way people heal; today announced it has achieved additional distribution penetration into the Canadian market. ActiPatch Therapy is now being carried by leading drug and pharmacy chains in Canada and strong reorders are taking place. These Canadian reorders and other growing international distribution is expected to allow BioElectronics to continue to meaningfully increase its revenue base.
Retail presentation of ActiPatch products in the Canadian market is through new counter top and free standing floor display units some of which hold the newly designed ActiPatch product brochure that outlines effective use of the product for the treatment of back and other chronic musculoskeletal conditions. Over the past few months the company has also made strong progress with the two largest pharmacy wholesalers within the Canadian market. These wholesalers are now making ActiPatch Therapy available to all of the smaller pharmacies throughout the country.
"We are very excited about our growing distribution and retail sales follow through within the Canadian market commented Andrew Whelan, CEO and President of BioElectronics Corp. "We now receiving reorders from the distribution channel, which demonstrates that demand for ActiPatch products within the Canadian market continues to grow. The growth in our Canadian revenue stream, when combined with the strong results we are seeing in other international markets, will allow the company to report record revenues over the coming quarters. It is clearly an exciting time for BioElectronics Corporation, our international distributors and our shareholders."
About BioElectronics Corporation
BioElectronics Corporation is the maker of the ActiPatch(R) Therapy. ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for about a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling. ActiPatch Therapy is approved by Health Canada for the relief of pain in musculoskeletal complaints. The US government's food and drug administration (FDA) has cleared the use of the product for reducing edema (swelling) following blepharoplasty and the European Union has approved the product as a class two pulsed electromagnetic medical device as have numerous other international record for agencies.
Safe Harbor Statement
This news release contains forward-looking statements related to future
growth and earnings opportunities. Such statements are based upon certain
assumptions and assessments made by management of both companies In light
of current conditions, expected future developments and other factors it
believes to be appropriate. Actual results may differ as a result of
factors over which the company has no control.
Joe Noel, Emerging Growth Research LLP
|SOURCE BioElectronics Corporation|
Copyright©2008 PR Newswire.
All rights reserved